Cargando…
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, from cancer to autoimmune disease. Perhaps the best studied target is the pan B-cell marker CD20. Indeed, the first mAb...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632755/ https://www.ncbi.nlm.nih.gov/pubmed/29046676 http://dx.doi.org/10.3389/fimmu.2017.01245 |